2 (SARS-CoV-2) have not been specifically investigated in kidney transplant recipient (KTRs).
Preliminary results suggest that among KTRs who received the first injection of an mRNA-…

To the editor: Several of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines use a nucleosidemodified, purified mRNA lipid nanoparticle-encapsulated …

Background and purpose Neurological manifestations in coronavirus disease (COVID)‐2019
may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for …

The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against
the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …

To the editor: Immunocompromised patients show an impaired vaccine-induced immune
response, resulting in an increased risk of severe coronavirus disease 2019 (COVID-19). 1 In …

Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …

Background. Data on coronavirus disease 2019 (COVID-19) in immunocompromised kidney
transplant recipients (KTR) remain scanty. Although markers of inflammation, cardiac injury, …

Introduction Kidney transplant recipients (KTRs) are prone to develop severe COVID-19
and are less well protected by vaccine than immunocompetent subjects. Thus, the use of …

A recent study demonstrated that a single dose of a severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological …